U.S., March 29 -- ClinicalTrials.gov registry received information related to the study (NCT06900010) titled 'A Study to Evaluate CM336 in Adults with Autoimmune Bullous Disease' on March 23.
Brief Summary: to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Autoimmune Bullous Disease
Intervention:
BIOLOGICAL: CM336 Injection
subcutaneous CM336 administration
Recruitment Status: RECRUITING
Sponsor: Shandong First Medical University
Published by HT Digital Content Services with permission from Health Daily Digest....